ArticleJAAD international2026

Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, in patients with moderate to severe scalp psoriasis: Efficacy and safety results through week 16 in a phase 3b/4, multicenter, randomized, double-blinded, placebo-controlled trial (PSORIATYK SCALP).

Kristina Callis Duffin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.